**REVIEW ARTICLE** 



## Pain relief in chronic pancreatitis: endoscopic or surgical treatment? a systematic review with meta-analysis

Pastor Joaquín Ortiz Mendieta<sup>1</sup> · Vitor Massaro Takamatsu Sagae<sup>1</sup> · Igor Braga Ribeiro<sup>1</sup> · · Diogo Turiani Hourneaux de Moura<sup>1</sup> · Maria Vitória Cury Vieira Scatimburgo<sup>1</sup> · Bruno Salomao Hirsch<sup>1</sup> · Rodrigo Silva de Paula Rocha<sup>1</sup> · Thiago Arantes de Carvalho Visconti<sup>1</sup> · Sergio A. Sánchez-Luna<sup>2,3</sup> · Wanderley Marques Bernardo<sup>1</sup> · Eduardo Guimarães Hourneaux de Moura<sup>1</sup>

Received: 6 December 2020 / Accepted: 17 April 2021 / Published online: 4 May 2021 © Springer Science+Business Media, LLC, part of Springer Nature 2021

## Abstract

**Background and aims** Pain is one of the consequences of chronic pancreatitis (CP) that has the greatest impact on the quality of life of patients.

Endoscopic and surgical interventions, by producing a decrease in intraductal pancreatic pressure, can provide pain relief. This is the first systematic review that includes only randomized clinical trials (RTCs) comparing outcomes in the short-term (less than 2 years) and long-term (more than 2 years) between these two types of interventions.

**Material and methods** A comprehensive search of multiple electronic databases to identify RTCs comparing short and long-term pain relief, procedural complications, and days of hospitalization between endoscopic and surgical interventions was performed following the PRISMA guidelines.

**Results** Three RCTs evaluating a total of 199 patients (99 in the endoscopy group and 100 in the surgery group) were included in this study. Surgical interventions provided complete pain relief, with statistical difference, in the long-term (16,4% vs 35.7%; RD 0.19; 95% CI 0.03–0.35; p=0.02; I2=0%), without significant difference in short-term (17.5% vs 31.2%; RD 0.14; 95% CI –0.01–0.28; p=0.07; I2=0%) when compared to endoscopy. There was no statistical difference in short-term (17.5% vs 28.1%; RD 0.11; 95% CI –0.04–0.25; p=0.15; I2=0%) and long-term (34% vs 41.1%; RD 0.07; 95% CI –0.10–0.24; p=0.42; I2 0%) in partial relief of pain between both interventions. In the short-term, both complications (34.9% vs 29.7%; RD 0.05; 95% CI –0.10–0.21; p=0.50; I2=48%) and days of hospitalization (MD –1.02; 95% CI –2.61–0.58; p=0.21; I2=0%) showed no significant differences.

**Conclusion** Surgical interventions showed superior results when compared to endoscopy in terms of complete long-term pain relief. The number of complications and length of hospitalization in both groups were similar.

Keywords Chronic pancreatitis (CP) · Endoscopy · Lithotripsy · Surgery · Pain

Chronic pancreatitis (CP) is an irreversible, multifactorial, and fibroinflammatory disease that has a detrimental impact on the quality and life expectancy of affected patients [1]. This is clinically manifested by abdominal pain, malnutrition, and endocrine and exocrine pancreatic insufficiency, whose causative or contributing factor to its progression is categorized by a classification system, depending on whether it is toxic-metabolic, idiopathic, genetic, autoimmune,

☑ Igor Braga Ribeiro igorbraga1@gmail.com recurrent and severe acute pancreatitis, or obstructive (TIGAR-0\_V2) [2, 3].

Pain, the most common presenting symptom in CP, has a poorly understood and complex pathophysiology [3–5]. As it is a somewhat subjective symptom, scales have been developed for its measurement, including the Izbicki scale [6], which is specific for chronic pancreatitis, and the Mezlack scale [7] which is more widely used scale. Amongst the complications of CP, strictures, and calcifications in the main pancreatic duct (MPD), by causing obstruction and an increase in MPD pressure, are the main etiology of pain. Nevertheless, neuropathic nerve inflammation, pancreatic cancer, peripancreatic fluid collections, and extra-pancreatic

Extended author information available on the last page of the article

complications (peptic ulcer disease and duodenal/bile duct strictures) can contribute or be the etiology for the pain [2].

Both endoscopic and surgical interventions aim at relieving pain and treating local complications [8]. Endoscopic interventions such as pneumatic dilation of MPD strictures, stent placement, and stone removal/lithotripsy via endoscopic retrograde cholangiopancreatography (ERCP) alongside extracorporeal shock wave lithotripsy (ESWL) work by relieving intraductal pressure [4, 9]. Surgical therapies can be classified into decompression, resection, and mixed techniques. These are performed accordingly to the characteristics of the patient, anatomical alterations of the pancreatic gland and its ductal system, and the presence of an associated inflammatory pancreatic head mass [10–12]. Also, local expertise plays a role in ultimately determining the most appropriate surgical intervention.

This study aims to evaluate the impact of endoscopic interventions in comparison with surgical procedures on pain relief, complications, and hospitalization time in patients with chronic obstructive pancreatitis.

## Material and methods

## **Protocol registration**

This study was performed in conformity with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, and it was registered in the International Prospective Register of Systematic Reviews (PROS-PERO) database under the file number CRD42020200449. The study was approved by the Ethics Committee of Hospital das Clínicas, Faculty of Medicine at The University of São Paulo.

## **Eligibility criteria**

Data search was made without limitations of language or publication date. The eligibility criteria were randomized clinical trials (RCTs) comparing endoscopic therapy (associated or not with lithotripsy) versus surgery for the treatment of chronic pancreatitis in patients over 18 years of age, with dilation in the main pancreatic duct, associated with proximal stenosis, or the presence of stones in it, with or without increased pancreatic head volume. The exclusion criteria were studies that compared another type of therapy different from those mentioned in the inclusion criteria, or studies that included neoplastic pathologies.

#### Information sources

from their inception until November 2020. The search strategy is described in supplementary Appendix 1.

#### Study selection and data collection process

Two researchers reviewed the title and abstract of each article after the removal of duplicated articles. Articles that were found to be relevant were selected for full-text review. The final decision on the selection of the studies was based on predetermined inclusion and exclusion criteria. Any disagreement on the selection of the studies was resolved by consensus with a third experienced researcher. The primary outcome was complete and partial pain relief. The secondary outcomes were complications and hospital stay.

Due to the variability of follow-up time between studies, we grouped them according to the time of evaluation of their results, in short-term follow-up (less than 2 years) and longterm follow-up (more than two years).

## Data items

The following data were extracted: name of the first author, year of publication, type of study, population (characteristics and number of patients), intervention or test (characteristics and number of patients), comparison (characteristics and number of patients), follow-up time, and outcomes (number of events) (Table 1).

## **Evaluation of biases and quality of studies**

The selected studies were all RCTs and the risks of bias were defined by version 2 of the Cochrane Risk-of-Bias tool for Randomized Trials (RoB2) [13] (Table 2). The quality of evidence, expressed in high, moderate, low, and very low, was assessed utilizing the objective criteria from GRADE (Grading Recommendations Assessment, Development, and Evaluation) for each of the pre-specified results and outcomes using GRA-DEpro—Guideline Development Tool software (McMaster University, 2015; Evidence Prime, Inc., Ontario, Canada).

## **Data analysis**

The data of interest extracted from the selected studies were meta-analyzed using RevMan software (Review Manager Software version 5.4—Cochrane Collaboration Copyright<sup>©</sup> 2020).

For dichotomous variables, the risk difference was determined by calculating the number of events and the sample size using the Mantel Haenszel test with a 95% confidence interval. For continuous variables the mean or median with standard deviation and the total number of patients were used, employing the inverse variance test with a 95% confidence interval. When the results were not presented with standard deviation, the estimation of a sample's mean and

								Outcomes				
Autor	Year	Study design	Autor Year Study design Follow-up time Patient Inte	Patient	Intervention/comparison ESWL Pain measure-	ESWL	Pain measure-	Pain relief		Technical	Complications	Technical Complications Days of hospitalization
							ment 1nstru- ments	Complete Partial	Partial	success		
Issa Y	Issa Y 2020 RCT	RCT	18 months	88	44 ENDOSCOPY	Yes	Melzack score	8	8		11	10 + -4.91
					44 SURGERY	No		12	11		12	11 + -2.32
Cahen	Cahen 2011	RCT	2 years	39	<b>19 ENDOSCOPY</b>	Yes	Izbicki score	3	б	10	11	8 + -36.98
					20 SURGERY	No		8	7	20	7	11 + -15.61
			7 years	39	<b>19 ENDOSCOPY</b>	Yes		4	2	9	6	13 + -67.87
					20 SURGERY	No		8	4	18	1	11 + -98.18
Dité	2003 RCT	RCT	5 years	72	<b>36 ENDOSCOPY</b>	No	Izbicki score	5	17			
					36 SURGERY	No		12	19			
RCT R	andomize	ed clinical trial,	RCT Randomized clinical trial, ESWL Extracorporeal shock wave lithotripsy	eal shock	wave lithotripsy							

 Table 1
 Characteristics of included studies

variance from its median and range using the Hozo test [14] was performed.

In both dichotomous and continuous variables, a fixed effect was used when the heterogeneity was <50% and a random effect when >50%. Values of p < 0.05 were considered statistically significant. Heterogeneity was calculated using the Higgins test (I2), ranging from 0% to 100%. I2 values higher than 50% were considered substantial heterogeneity [14, 15].

Due to the low number of identified clinical trials and the low heterogeneity between them, funnel plots were not useful to assess the presence of publication bias. Therefore, it was not necessary to use them.

## Results

# Literature search results and characteristics of included studies

The initial search strategy identified 15,327 records. After the removal of duplicates, evaluation of the titles and abstracts, and a full reading of 13 studies, three studies were selected [16-18]. Figure 1 shows the selection process.

The selected studies compared endoscopic therapy versus surgical procedures for the management of chronic pancreatitis, with some variations regarding the technique performed, patient characteristics, and follow-up time. Three RCTs [16–18] evaluated a total of 199 patients, with 99 in the intervention group (endoscopy) and 100 in the comparison group (surgery). One of the RCTs [18] included both patients who accepted and did not accept randomization, and to maintain the quality of the evidence, only data from randomized patients were extracted for the analysis. Another author evaluates the same population in two different publications, one with a 2-year follow-up [19] and the other five years after the end of the first evaluation [17]. We extracted the data from both publications (Table 1).

## Results

## Pain relief

#### **Complete pain relief**

After the subgroup analysis, 2 RCTs [17, 18], with a total of 111 patients (55 in the endoscopy group and 56 in the surgery group), showed a significant difference in long-term pain relief in favor of surgery group (RD 0.19; 95% CI 0.03, 0.35; p = 0.02;  $I^2 = 0\%$ ). High quality of evidence (Table 3). No significant difference was observed in the short term (RD 0.14; 95% CI -0.01, 0.28; p = 0.07;  $I^2 = 0\%$  (Fig. 2). High quality of evidence (Table 3).

Table 2Rob 2 Risk of biasassessment

Study ID	Randomization process	Deviations from intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported result	Overall			
Issa 2020	+	+	+	+	?		+	Low risk	
Cahen 2011	+	+	+	+	+	+	?	Some concerns	S
Cahen 2007	+	+	+	+	+	+	O	High risk	
Dité 2003	•	?	+	?	+	•			




Fig. 1 Flow diagram showing study selection process for meta-analysis

Certainty assessment						No of natients		Effect		Certainty	Imnortance
No of studies Study design		Risk of bias Inconsistency Indirectness Imprecision	Indirectness	Imprecision	Other considera- tions	Endoscopy	Surgery	Relative (95% CI)	Absolute (95% CI)	6	
Complete pain relief—Middle term 2 Randomized Not trials	le term Not serious <sup>a</sup> Not serious	Not serious	Not serious	serious Not serious	None	11/63 (17.5%)	20/64 (31.3%)	Not estimable	140 fewer per 1.000 (from 280 fewer to 10 more)	ФФФ нісн	
Complete pain relief—long term 2 Randomized N triåls	term Not serious <sup>b</sup> Not serious	Not serious	Not serious	serious Not serious	None	9/55 (16.4%)	20/56 (35.7%)	Not estimable 190 fewer per 1.00 (from 35	<b>190 fewer</b> per 1.000 (from 350	ФФФ нісн	
Partial pain relief—Middle term 2 Randomized N trials	erm Not serious <sup>a</sup> Not serious	Not serious	Not serious	Serious <sup>c</sup>	None	11/63 (17.5%)	18/64 (28.1%)	Not estimable	to 30 fewer) 110 fewer per 1.000 (from 250 former 6.40	⊕⊕⊕⊖ MODER- ATE	
Partial pain relief—Long term 2 Randomized trials		Not serious <sup>b</sup> Not serious	Not serious	Very serious <sup>c</sup> None	None	19/55 (34.5%)	23/56 (41.1%)	Not estimable	7		
Complications—Middle term 2 Randomized trials		Not serious <sup>a</sup> Not serious	Not serious	serious Very serious <sup>c</sup> None	None	22/63 (34.9%)	19/64 (29.7%)	Not estimable	ы С		
Days of hospitalization—Middle term 2 Randomized Not ser trials	ddle term Not serious <sup>a</sup> Not serious	Not serious	Not serious	Not serious	None	63	64	I	100 more) MD 1.02 lower (2.61 lower to 0 58 hioher)	ФФФ нісн	

🙆 Springer

<sup>b</sup>Bias in randomization <sup>c</sup>Wide confidence interval

<sup>a</sup>Bias in selection of the reported result

	Endosc		Surge	-		Risk Difference (Non-event)	Risk Difference (Non-event)
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% Cl
1.1.1 Short term							
Cahen 2011	3	19	8	20	16.4%	0.24 [-0.03, 0.51]	
Issa 2020	8	44	12	44	37.0%	0.09 [-0.08, 0.26]	
Subtotal (95% CI)		63		64	53.4%	0.14 [-0.01, 0.28]	
Total events	11		20				
Heterogeneity: Chi <sup>2</sup> =	0.85, df =	1 (P =	0.36); I <sup>2</sup> =	0%			
Test for overall effect:	Z=1.84 (	P = 0.0	7)				
1.1.2 Long term							
Cahen 2011	4	19	8	20	16.4%	0.19 [-0.09, 0.47]	
Dité 2003	5	36	12	36	30.3%	0.19 [0.00, 0.39]	
Subtotal (95% CI)		55		56	46.6%	0.19 [0.03, 0.35]	
Total events	9		20				
Heterogeneity: Chi <sup>2</sup> =	0.00, df =	1 (P =	0.98); l <sup>2</sup> =	0%			
Test for overall effect:	Z= 2.38 (	P = 0.0	2)				
Total (95% CI)		118		120	100.0%	0.16 [0.06, 0.27]	
Total events	20		40				
Heterogeneity: Chi <sup>2</sup> =	1.13, df =	3 (P = 1	0.77); I <sup>2</sup> =	:0%			-0.5 -0.25 0 0.25 0
Test for overall effect:	Z= 2.97 (	P = 0.0	03)				-0.5 -0.25 0 0.25 0 Favors [Endoscopy] Favors [Surgery]
Test for subaroup diff				1 (P = 1	0.62), I <sup>z</sup> =	0%	Favors (Endoscopy) Favors (Surgery)

## Fig. 2 Forest plot of complete pain relief:Overall

	Endosc	opy	Surge	егу		Risk Difference (Non-event)	Risk Difference (Non-event)
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% CI
1.2.1 Short term							
Cahen 2011	3	19	7	20	16.4%	0.19 [-0.07, 0.46]	
Issa 2020	8	44	11	44	37.0%	0.07 [-0.10, 0.24]	
Subtotal (95% CI)		63		64	53.4%	0.11 [-0.04, 0.25]	
Total events	11		18				
Heterogeneity: Chi <sup>2</sup> =	0.59, df =	1 (P =	0.44); I <sup>2</sup> =	0%			
Test for overall effect:	Z=1.45 (	P = 0.1	5)				
1.2.2 Long term							
Cahen 2011	2	19	4	20	16.4%	0.09 [-0.13, 0.32]	
Dité 2003	17	36	19	36	30.3%	0.06 [-0.18, 0.29]	
Subtotal (95% CI)		55		56	46.6%	0.07 [-0.10, 0.24]	
Total events	19		23				
Heterogeneity: Chi <sup>2</sup> =	0.06, df =	1 (P =	0.80); I² =	0%			
Test for overall effect:	Z = 0.80 (	P = 0.4	2)				
Total (95% CI)		118		120	100.0%	0.09 [-0.02, 0.20]	
Total events	30		41				
Heterogeneity: Chi <sup>2</sup> =	0.72, df=	3 (P = 1	0.87); I <sup>2</sup> =	0%		-	
Test for overall effect:							-0.2 -0.1 0 0.1 0.2
Test for subgroup diffe				1 (P = 1	0.74), I <sup>2</sup> =	0%	Favors [Endoscopy] Favors [Surgery]

## Fig. 3 Forest plot of partial pain relief

	Endosc	ору	Surge	ery		Risk Difference	Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% Cl
Cahen 2011	11	19	7	20	30.7%	0.23 [-0.08, 0.53]	
Issa 2020	11	44	12	44	69.3%	-0.02 [-0.21, 0.16]	
Total (95% CI)		63		64	100.0%	0.05 [-0.10, 0.21]	
Total events	22		19				
Heterogeneity: Chi <sup>2</sup> =	1.94, df=	1 (P =	0.16); I <sup>2</sup> =	48%			-0.5 -0.25 0 0.25 0.5
Test for overall effect:	Z=0.68 (	(P = 0.5	0)				Favors [Endoscopy] Favors [Surgery]

Fig. 4 Forest plot of complications



Fig. 5 Forest plot of days of hospitalization

#### Partial pain relief

No statistical difference was observed in the subgroup analysis. Two RCTs [16, 19] evaluated partial pain relief in the short term, with a total of 127 patients (63 in the endoscopy group and 64 in the surgery group) (RD 0.11; 95% CI –0.04, 0.25; p=0.15;  $I^2=0\%$ ) (Fig. 3). Moderate quality of evidence (Table 3). Two RCTs [17, 18] evaluated long-term partial relief in 111 patients (55 in the endoscopy group and 56 in the surgery group) (RD 0.07; 95% CI –0.10, 0.24; p=0.42;  $I^2=0\%$ ) (Fig. 3). Low quality of evidence (Table 3).

#### Complications

Two RCTs [16, 19], with a total of 127 patients (63 in the endoscopy group and 64 in the surgery group), were compared regarding the post-procedure complications in the short term, without a significant difference (RD 0.05; 95% CI -0.10, 0.21; p = 0.50;  $I^2 = 48\%$ ) between them (Fig. 4). Low quality of evidence (Table 3).

## **Days of hospitalization**

Two RCTs [16, 19], with a total of 127 patients (63 in the endoscopy group and 64 in the surgery group), were compared regarding the days of hospitalization in the short term, with no significant difference (MD -1.02; 95% CI -2.61, 0.58; p = 0.21; I<sup>2</sup> = 0%) between them (Fig. 5). High quality of evidence (Table 3).

## Discussion

Endoscopic therapy-associated or not with ESWL- and surgical interventions are widely used options for the treatment of patients with pain caused by chronic pancreatitis. Both treatments focus on relieving pancreatic intraductal pressure without taking into account other possible mechanisms that could account for this symptom [20], which could explain the number of patients who do not achieve complete or partial relief of pain in both types of therapies. Other meta-analyses have evaluated comparative studies between surgery and endoscopy. One of them [21] evaluated pain relief in middle and long-term subgroups, showing a significant difference in both in favor of the surgical intervention group. However, they used the same population of one of the randomized studies for the analysis of both subgroups [18]. Also, the follow-up time of the results shows a very wide difference (2 compared to 5 years). The other meta-analysis [22] showed a significant difference in complete long-term pain relief in favor of surgery. However, it included randomized and non-randomized patients from one of their studies [18] which decreases the quality of the evidence.

In our meta-analysis, randomized studies showed that surgical interventions had better results than endoscopy, with a significant difference regarding complete pain relief when their long-term results were compared. We found no statistical difference in the short-term, which is partially consistent with the aforementioned meta-analyses [21, 22]. This could be mainly due to the long-term recurrences of pain observed in part of the cases undergoing endoscopic therapy. Unlikely surgery, in which there is a permanent anatomical alteration that allows decompression of the gland via a wide anastomosis with the intestinal loop that significantly reduces the likelihood of recurrent strictures or stone impactions.

Although it was not the reason for the analysis of the present study, one clinical trial reports similar rates of pain relief when a complete clearance was achieved via endoscopic therapy, either with or without the application of ESWL [16]. We thus believe that endoscopic interventions can be considered in the first instance in selected cases (those that have the possibility of reaching clearance or relief of obstruction) since a decompression surgery would not achieve additional benefit for this symptom if it does not improve after endoscopic therapy. Surgery could then be performed when there is a recurrence of a stricture or pancreatolithiasis, or in the event of a failure with endoscopic treatment. We find this approach to be recommended in different guidelines [23-25], amongst these, the European Society of Gastrointestinal Endoscopy (ESGE) which recommends endoscopic therapy and ESWL as the first treatment option in obstructions at the level of the head or body of the pancreas, followed by a reevaluation of the response 6 to 8 weeks later.

Regarding complications, no statistical difference was found in the short-term. Because only one randomized study reported long-term data, this comparison was not possible [17]. Although surgical interventions are more invasive and more complications are expected (wound infection, dehiscence, or fistulas), this generally requires a single-stage procedure. On the opposite side, endoscopic therapy requires multiple sessions, leading to a higher chance of complications (cholecystitis, bleeding, or cholangitis) or exacerbations of pancreatitis. Only one of the studies reports an early death, four days after ESWL, caused by a perforated duodenal ulcer in a patient using non-steroidal anti-inflammatory drugs (NSAIDs) [19].

There was no statistical difference in the average days of hospitalization in the short-term, and it was not possible to meta-analyze this result in the long-term. Even though endoscopic therapies are an outpatient procedure, in some cases, the hospitalizations were related to post-procedural complications. We must also mention that one of the studies [16] reported in the endoscopy arm -in addition to hospitalizations secondary to endoscopic complications-, hospitalizations for surgical procedures that were performed in the event of failure of the endoscopic treatment.

This study has some limitations such as the low number of identified clinical trials, the differences in terms of follow-up time, patient characteristics, pain measurement scales used and time interval for evaluating them, and types of treatments performed across studies (Table 2). One study excluded patients with an increased volume of the head of the pancreas [17]. There are also differences regarding the type of lithotripsy. In one study, ESWL was not offered in any case of lithiasis of the main pancreatic duct, and instead, mechanical lithotripsy was performed [18]. Extracorporeal shock wave lithotripsy can be performed on an outpatient basis, and in addition to relieving the stone obstruction, some of its effects on pain could be related to changes in nociception via some effects on the intra-pancreatic nerves [26]. Despite this, surgical interventions (particularly resection techniques) continue to be superior to ERCP even when associated with ESWL. Nevertheless, CP is a complex, multifactorial, and difficult-to-treat disease, with different responses to each type of intervention. Also, each study individually shows homogeneous populations between groups, observing high-quality evidence in three randomized clinical trials.

In conclusion, in the treatment of chronic obstructive pancreatitis, surgical interventions showed superior benefits to endoscopic therapies in terms of pain relief in the long-term. The number of complications and length of hospitalization in both groups were similar.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00464-021-08515-w.

#### Acknowledgements None.

Author contributions Mendieta, PJO: acquisition of data, analysis, interpretation of data, drafting the article, revising the article, final approval; Sagae, VMT: acquisition of data, analysis, interpretation of data, drafting the article, revising the article, final approval; Ribeiro, IB: analysis and interpretation of data, revising the article; de Moura, DTH: analysis and interpretation of data, revising the article; Scatimburgo, MVCV: analysis and interpretation of data, revising the article; Rocha, RSP: analysis and interpretation of data, revising the article; Visconti, TAC: analysis and interpretation of data, revising the article; Sánchez-Luna, SA: revising the article and linguistic correction; Bernardo, WM: analysis and interpretation of data, drafting the article, final approval; de Moura, EGH analysis and interpretation of data, drafting the article, final approval.

Funding None.

#### Declarations

**Disclosures** Dr. Eduardo Guimarães Hourneaux de Moura reports personal fees from Boston Scientific and Olympus but these were not relevant to this manuscript. Drs. Pastor Joaquín Ortiz Mendieta, Vitor Massaro Takamatsu Sagae, Igor Braga Ribeiro, Diogo Turiani Hourneaux de Moura, Maria Vitória Cury Vieira Scatimburgo, Bruno Salomao Hirsch, Rodrigo Silva de Paula Rocha, Thiago Arantes de Carvalho Visconti, Sergio A. Sánchez-Luna, and Wanderley Marques Bernardo have nothing to disclose.

**Ethical approval** The study was approved by the Research Ethics Committee of the University of São Paulo School of Medicine Hospital das Clínicas.

## References

- Hoffmeister A, Mayerle J, Beglinger C, Büchler M, Bufler P, Dathe K, Fölsch U, Friess H, Izbicki J, Kahl S, Klar E, Keller J, Knoefel W, Layer P, Loehr M, Meier R, Riemann J, Rünzi M, Schmid R, Schreyer A, Tribl B, Werner J, Witt H, Mössner J, Lerch M (2015) English language version of the S3-consensus guidelines on chronic pancreatitis: definition, aetiology, diagnostic examinations, medical, endoscopic and surgical management of chronic pancreatitis. Z Gastroenterol 53:1447–1495. https://doi. org/10.1055/s-0041-107379
- Pham A, Forsmark C (2018) Chronic pancreatitis: review and update of etiology, risk factors, and management. F1000Research. https://doi.org/10.12688/f1000research.12852.1
- Whitcomb DC (2019) Pancreatitis. Clin Transl Gastroenterol. https://doi.org/10.14309/ctg.00000000000027
- Udd M, Kylänpää L, Kokkola A (2020) The role of endoscopic and surgical treatment in chronic pancreatitis. Scand J Surg 109:69–78. https://doi.org/10.1177/1457496920910009
- Drewes AM, Krarup AL, Detlefsen S, Malmstrom M-L, Dimcevski G, Funch-Jensen P (2008) Pain in chronic pancreatitis: the role of neuropathic pain mechanisms. Gut 57:1616–1627. https:// doi.org/10.1136/gut.2007.146621
- Izbicki JR, Bloechle C, Broering DC, Kuechler T, Broelsch CE (1998) Longitudinal v-shaped excision of the ventral pancreas for small duct disease in severe chronic pancreatitis. Ann Surg 227:213–219. https://doi.org/10.1097/00000658-19980 2000-00010

- Melzack R (1975) The McGill Pain questionnaire: major properties and scoring methods. Pain 1:277–299. https://doi.org/10. 1016/0304-3959(75)90044-5
- Nguyen-Tang T, Dumonceau J-M (2010) Endoscopic treatment in chronic pancreatitis, timing, duration and type of intervention. Best Pract Res Clin Gastroenterol 24:281–298. https://doi.org/10. 1016/j.bpg.2010.03.002
- Proença IM, dos Santos MEL, de Moura DTH, Ribeiro IB, Matuguma SE, Cheng S, McCarty TR, Do Monte Jr ES, Sakai P, De Moura EGH (2020) Role of pancreatography in the endoscopic management of encapsulated pancreatic collections – review and new proposed classification. World J Gastroenterol 26:7104–7117. https://doi.org/10.3748/wjg.v26.i45.7104
- Shanbhogue KP, Pourvaziri A, Jeyaraj SK, Kambadakone A (2020) Endoscopic and surgical treatment options for chronic pancreatitis: an imaging perspective. Abdom Radiol 45:1397–1409. https://doi.org/10.1007/s00261-019-02249-z
- Hafezi-Nejad N, Singh VK, Johnson SI, Makary MA, Hirose K, Fishman EK, Zaheer A (2016) Surgical approaches to chronic pancreatitis: indications and imaging findings. Abdom Radiol 41:1980–1996. https://doi.org/10.1007/s00261-016-0775-y
- Drewes AM, Bouwense SAW, Campbell CM, Ceyhan GO, Delhaye M, Demir IE, Garg PK, van Goor H, Halloran C, Isaji S, Neoptolemos JP, Olesen SS, Palermo T, Pasricha PJ, Sheel A, Shimosegawa T, Szigethy E, Whitcomb DC, Yadav D (2017) Guidelines for the understanding and management of pain in chronic pancreatitis. Pancreatology 17:720–731. https://doi.org/10.1016/j.pan.2017.07.006
- Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Emberson JR, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:14898. https:// doi.org/10.1136/bmj.14898
- Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13. https://doi.org/10.1186/1471-2288-5-13
- Cochrane (2019) Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane
- 16. Issa Y, Kempeneers MA, Bruno MJ, Fockens P, Poley J-W, Ahmed Ali U, Bollen TL, Busch OR, Dejong CH, van Duijvendijk P, van Dullemen HM, van Eijck CH, van Goor H, Hadithi M, Haveman J-W, Keulemans Y, Nieuwenhuijs VB, Poen AC, Rauws EA, Tan AC, Thijs W, Timmer R, Witteman BJ, Besselink MG, van Hooft JE, van Santvoort HC, Dijkgraaf MG, Boermeester MA (2020) Effect of early surgery vs endoscopy-first approach on pain in patients with chronic pancreatitis. JAMA 323:237. https://doi.org/ 10.1001/jama.2019.20967
- 17. Cahen DL, Gouma DJ, Laramée P, Nio Y, Rauws EAJ, Boermeester MA, Busch OR, Fockens P, Kuipers EJ, Pereira SP, Wonderling D, Dijkgraaf MGW, Bruno MJ (2011) Long-term outcomes of endoscopic vs surgical drainage of the pancreatic

duct in patients with chronic pancreatitis. Gastroenterology 141:1690–1695. https://doi.org/10.1053/j.gastro.2011.07.049

- Díte P, Ruzicka M, Zboril V, Novotný I (2003) A prospective, randomized trial comparing endoscopic and surgical therapy for chronic pancreatitis. Endoscopy 35:553–558. https://doi.org/10. 1055/s-2003-40237
- Cahen DL, Gouma DJ, Nio Y, Rauws EAJ, Boermeester MA, Busch OR, Stoker J, Laméris JS, Dijkgraaf MGW, Huibregtse K, Bruno MJ (2007) Endoscopic versus surgical drainage of the pancreatic duct in chronic pancreatitis. N Engl J Med 356:676–684. https://doi.org/10.1056/NEJMoa060610
- Drewes AM, Kempeneers MA, Andersen DK, Arendt-Nielsen L, Besselink MG, Boermeester MA, Bouwense S, Bruno M, Freeman M, Gress TM, van Hooft JE, Morlion B, Olesen SS, van Santvoort H, Singh V, Windsor J (2019) Controversies on the endoscopic and surgical management of pain in patients with chronic pancreatitis: pros and cons! Gut 68:1343–1351. https:// doi.org/10.1136/gutjnl-2019-318742
- Ahmed Ali U, Pahlplatz JM, Nealon WH, van Goor H, Gooszen HG, Boermeester MA (2015) Endoscopic or surgical intervention for painful obstructive chronic pancreatitis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD007884.pub3
- Jawad ZAR, Kyriakides C, Pai M, Wadsworth C, Westaby D, Vlavianos P, Jiao LR (2017) Surgery remains the best option for the management of pain in patients with chronic pancreatitis: a systematic review and meta-analysis. Asian J Surg 40:179–185. https://doi.org/10.1016/j.asjsur.2015.09.005
- Dumonceau J-M, Delhaye M, Tringali A, Arvanitakis M, Sanchez-Yague A, Vaysse T, Aithal G, Anderloni A, Bruno M, Cantú P, Devière J, Domínguez-Muñoz J, Lekkerkerker S, Poley J-W, Ramchandani M, Reddy N, van Hooft J (2019) Endoscopic treatment of chronic pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Updated August 2018. Endoscopy 51:179–193. https://doi.org/10.1055/a-0822-0832
- 24. Löhr JM, Dominguez-Munoz E, Rosendahl J, Besselink M, Mayerle J, Lerch MM, Haas S, Akisik F, Kartalis N, Iglesias-Garcia J, Keller J, Boermeester M, Werner J, Dumonceau J-M, Fockens P, Drewes A, Ceyhan G, Lindkvist B, Drenth J, Ewald N, Hardt P, de Madaria E, Witt H, Schneider A, Manfredi R, Brøndum FJ, Rudolf S, Bollen T, Bruno M (2017) United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United Eur Gastroenterol J 5:153–199. https://doi.org/10.1177/2050640616684695
- Gardner TB, Adler DG, Forsmark CE, Sauer BG, Taylor JR, Whitcomb DC (2020) ACG clinical guideline. Am J Gastroenterol 115:322–339. https://doi.org/10.14309/ajg.000000000000535
- Forsmark CE (2013) Management of chronic pancreatitis. Gastroenterology 144:1282-1291.e3. https://doi.org/10.1053/j.gastro. 2013.02.008

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## **Authors and Affiliations**

Pastor Joaquín Ortiz Mendieta<sup>1</sup> · Vitor Massaro Takamatsu Sagae<sup>1</sup> · Igor Braga Ribeiro<sup>1</sup> · · Diogo Turiani Hourneaux de Moura<sup>1</sup> · Maria Vitória Cury Vieira Scatimburgo<sup>1</sup> · Bruno Salomao Hirsch<sup>1</sup> · Rodrigo Silva de Paula Rocha<sup>1</sup> · Thiago Arantes de Carvalho Visconti<sup>1</sup> · Sergio A. Sánchez-Luna<sup>2,3</sup> · Wanderley Marques Bernardo<sup>1</sup> · Eduardo Guimarães Hourneaux de Moura<sup>1</sup>

Pastor Joaquín Ortiz Mendieta joaquin.ortiz3489@gmail.com

Vitor Massaro Takamatsu Sagae vitorsagae@gmail.com

Diogo Turiani Hourneaux de Moura dthmoura@hotmail.com

Maria Vitória Cury Vieira Scatimburgo m.vitoriascatimburgo@hc.fm.usp.br

Bruno Salomao Hirsch brunosalomah@hotmail.com

Rodrigo Silva de Paula Rocha rodrigosprocha@gmail.com

Thiago Arantes de Carvalho Visconti thiago.visconti@yahoo.com.br

Sergio A. Sánchez-Luna ssanchezluna@gmail.com

Wanderley Marques Bernardo wmbernardo@usp.br

Eduardo Guimarães Hourneaux de Moura eduardoghdemoura@gmail.com

- <sup>1</sup> Serviço de Endoscopia Gastrointestinal do Hospital das Clínicas HCFMUSP, Departamento de Gastroenterologia, Faculdade de Medicina, Universidadede Sao Paulo, Sao Paulo, SP, Brazil
- <sup>2</sup> Center for Advanced Endoscopy, Division of Gastroenterology, Hepatology, and Nutrition, Allegheny Health Network, Pittsburgh, Pennsylvania, USA
- <sup>3</sup> Basil I. Hirschowitz Endoscopic Center of Excellence, Division of Gastroenterology and Hepatology, Department of Internal Medicine, The University Alabama at Birmingham, Birmingham,, Alabama, USA